Jim Cullen
Cullen Value Fund
Jim Cullen Novartis AG ADR stake
total: 74
Cullen Value Fund NVS trades
- Total transactions:
- 3
- New positions:
- 1
- Sold out:
- 1
- Reduced:
- 1
- Held since:
- 2019 Q3
- Held for:
- 10 quarters
- Latest activity:
- 2022 Q1
According to 2026 Q1 report, Jim Cullen doesn't hold any Novartis AG ADR (NVS) shares. To date, the estimated cost basis is nearly $86.9 for "buy" trades and estimated average "sell" price is $88.58. Cullen Value Fund first purchased NVS in 2019 Q3, initially acquiring 9,600 shares. Since the initial investment in Novartis AG ADR (NVS), Cullen Value Fund has made 2 more transactions.
When did Jim Cullen sell Novartis AG ADR (NVS)?
Jim Cullen sold off the entire Novartis AG ADR (NVS) position in 2022 Q1.
When did Jim Cullen buy Novartis AG ADR (NVS)?
Jim Cullen first invested in Novartis AG ADR (NVS) in 2019 Q3 at the reported quarter-end price of $86.90 per share.
What's the cost basis of Cullen Value Fund's NVS stake?
The estimated cost basis for Novartis AG ADR (NVS) stake is around $86.90 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $86.90
- Weighted AVG sell price:
- $88.58
Jim Cullen's historical trades in Novartis AG ADR
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.